GoKawiilFDA Logs Two Deaths Tied to Black-Market Retatrutide
The FDA has received at least two reports of deaths connected to unapproved, black-market versions of retatrutide, an experimental weight-loss drug still being developed by Eli Lilly and not yet approved for sale. CBS News reviewed documents describing one case involving a 41-year-old obese woman who died of cardiac arrest in July after obtaining the drug from an unverified source. The FDA has not confirmed the counterfeit drug was the definitive cause of death in either case, and an April Medpage Today report also described a non-fatal retatrutide overdose causing kidney injury and prolonged dehydration.
GoKawiil's interpretation of the reporting above, not reported fact.
These are the first public acknowledgments from health officials linking unapproved retatrutide to fatalities, which could intensify scrutiny of the thriving gray-market peptide trade that emerged before any official version of the drug reached pharmacies. The cases suggest regulators are tracking harms tied to compounded or counterfeit GLP-1-style drugs, even as enforcement against such products appears limited. The outcome of further investigation could shape how aggressively the FDA pursues illicit suppliers and whether Eli Lilly faces pressure to accelerate its own retatrutide approval process.
- FDA has received at least two death reports linked to black-market retatrutide.
- Retatrutide remains an unapproved Eli Lilly drug not yet sold through legal channels.
- Prior reports also documented non-fatal overdoses causing kidney damage and severe dehydration.
Source: futurism.com — Joe Wilkins, 2026-10-17
Published there as: “Black Market Retatrutide Linked to Multiple Deaths”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.